BR112017011555A2 - Composições que compreendem 2-((1-(2(4- fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona para o tratamento de esquizofrenia - Google Patents

Composições que compreendem 2-((1-(2(4- fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona para o tratamento de esquizofrenia

Info

Publication number
BR112017011555A2
BR112017011555A2 BR112017011555A BR112017011555A BR112017011555A2 BR 112017011555 A2 BR112017011555 A2 BR 112017011555A2 BR 112017011555 A BR112017011555 A BR 112017011555A BR 112017011555 A BR112017011555 A BR 112017011555A BR 112017011555 A2 BR112017011555 A2 BR 112017011555A2
Authority
BR
Brazil
Prior art keywords
piperidin
treatment
fluorofenyl
methil
isoindolin
Prior art date
Application number
BR112017011555A
Other languages
English (en)
Other versions
BR112017011555B1 (pt
Inventor
Okuyama Masahiro
Noel Nadine
Luthringer Remy
Werner Sandra
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of BR112017011555A2 publication Critical patent/BR112017011555A2/pt
Publication of BR112017011555B1 publication Critical patent/BR112017011555B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção fornece um novo polimorfo do composto (i): di-hidrato de monocloridrato de 2-((1-(2-(4-fluorofenil)-2-oxo-etil)piperidin-4-il)metil)isoindolin-1-ona, isto é, a forma (a) do composto (i)?ho?2h2o. composições farmacêuticas que compreendem a forma (a) do composto (i)?ho?2h2o e métodos relacionados de tratamento são também revelados.
BR112017011555-7A 2014-12-02 2015-11-30 Formulação farmacêutica compreendendo 2-((1-(2(4- fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1- ona e kit BR112017011555B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US62/086,691 2014-12-02
US201562248071P 2015-10-29 2015-10-29
US62/248,071 2015-10-29
PCT/US2015/062985 WO2016089766A1 (en) 2014-12-02 2015-11-30 Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia

Publications (2)

Publication Number Publication Date
BR112017011555A2 true BR112017011555A2 (pt) 2018-01-09
BR112017011555B1 BR112017011555B1 (pt) 2023-10-03

Family

ID=54848909

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011555-7A BR112017011555B1 (pt) 2014-12-02 2015-11-30 Formulação farmacêutica compreendendo 2-((1-(2(4- fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1- ona e kit

Country Status (26)

Country Link
US (6) US9458130B2 (pt)
EP (2) EP4063357A1 (pt)
JP (3) JP2018501217A (pt)
KR (1) KR102620681B1 (pt)
CN (2) CN111110677A (pt)
AU (4) AU2015355226B2 (pt)
BR (1) BR112017011555B1 (pt)
CA (1) CA2968977A1 (pt)
CL (2) CL2017001376A1 (pt)
CO (1) CO2017005498A2 (pt)
DK (1) DK3227273T3 (pt)
EA (1) EA201791226A1 (pt)
ES (1) ES2910528T3 (pt)
HU (1) HUE058212T2 (pt)
IL (3) IL301320A (pt)
MX (1) MX2017007065A (pt)
MY (1) MY185516A (pt)
PE (1) PE20171646A1 (pt)
PH (1) PH12017501007A1 (pt)
PL (1) PL3227273T3 (pt)
PT (1) PT3227273T (pt)
SG (1) SG11201704332YA (pt)
TW (1) TWI694069B (pt)
UA (1) UA122780C2 (pt)
WO (1) WO2016089766A1 (pt)
ZA (1) ZA201703481B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171646A1 (es) 2014-12-02 2017-11-13 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
KR20240005110A (ko) 2016-05-25 2024-01-11 미쓰비시 타나베 파마 코퍼레이션 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
PE20200732A1 (es) * 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
MA53437A (fr) * 2018-08-21 2021-06-30 Minerva Neurosciences Inc Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection
EP3990113A1 (en) * 2019-06-28 2022-05-04 Teva Czech Industries s.r.o. Solid state forms of roluperidone and salts thereof
US20230190870A1 (en) 2020-05-20 2023-06-22 The Board Of Trustees Of The University Of Illinois Method for Treating Lysosomal Storage Diseases with Histatin Peptides
US20230255953A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
EP0497843A4 (en) 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
US7166617B2 (en) * 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
AU2002304784A1 (en) * 2001-03-26 2002-10-08 Novartis Pharma Gmbh Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
DOP2006000125A (es) 2005-06-06 2006-12-31 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
BR112013001303A2 (pt) * 2010-07-20 2016-05-17 Cyrenaic Pharmaceuticals Inc métodos de uso de derivados de amida cíclica para tratar esquizofrenia
ES2914120T3 (es) * 2010-07-20 2022-06-07 Minerva Neurosciences Inc Procedimientos de uso de derivados de amida cíclicos para tratar trastornos mediados por el receptor sigma
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP2014508187A (ja) * 2011-03-17 2014-04-03 ルピン・リミテッド 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
PE20171646A1 (es) * 2014-12-02 2017-11-13 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
KR20240005110A (ko) 2016-05-25 2024-01-11 미쓰비시 타나베 파마 코퍼레이션 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
MA53437A (fr) 2018-08-21 2021-06-30 Minerva Neurosciences Inc Utilisation de rolupéridone pour traiter des symptômes et des troubles négatifs, augmenter la neuroplasticité et favoriser la neuroprotection

Also Published As

Publication number Publication date
KR20170106310A (ko) 2017-09-20
CA2968977A1 (en) 2016-06-09
CO2017005498A2 (es) 2017-09-20
AU2023258386A1 (en) 2023-11-23
IL252347B (en) 2021-01-31
PL3227273T3 (pl) 2022-05-30
TWI694069B (zh) 2020-05-21
PH12017501007A1 (en) 2017-12-18
EP4063357A1 (en) 2022-09-28
EP3227273A1 (en) 2017-10-11
CL2021000044A1 (es) 2021-06-04
AU2020204286B2 (en) 2021-06-17
US20180153871A1 (en) 2018-06-07
KR102620681B1 (ko) 2024-01-04
US20160152597A1 (en) 2016-06-02
US20170042877A1 (en) 2017-02-16
IL280052B1 (en) 2023-05-01
WO2016089766A1 (en) 2016-06-09
AU2015355226B2 (en) 2020-04-02
NZ770365A (en) 2023-10-27
CN107567444A (zh) 2018-01-09
JP2022105159A (ja) 2022-07-12
TW201632511A (zh) 2016-09-16
JP2018501217A (ja) 2018-01-18
US10258614B2 (en) 2019-04-16
AU2015355226A1 (en) 2017-06-08
MY185516A (en) 2021-05-19
PE20171646A1 (es) 2017-11-13
MX2017007065A (es) 2017-12-18
IL252347A0 (en) 2017-07-31
IL301320A (en) 2023-05-01
HUE058212T2 (hu) 2022-07-28
DK3227273T3 (da) 2022-05-02
AU2021229240B2 (en) 2023-08-24
US10799493B2 (en) 2020-10-13
US20200022968A1 (en) 2020-01-23
AU2020204286A1 (en) 2020-07-16
EP3227273B1 (en) 2022-02-09
US9730920B2 (en) 2017-08-15
AU2021229240A1 (en) 2021-10-07
SG11201704332YA (en) 2017-06-29
ZA201703481B (en) 2023-12-20
JP2020172531A (ja) 2020-10-22
US20210228561A1 (en) 2021-07-29
US20230201184A1 (en) 2023-06-29
BR112017011555B1 (pt) 2023-10-03
PT3227273T (pt) 2022-04-06
EA201791226A1 (ru) 2017-09-29
JP7069253B2 (ja) 2022-05-17
US9458130B2 (en) 2016-10-04
IL280052A (en) 2021-03-01
ES2910528T3 (es) 2022-05-12
NZ732033A (en) 2023-10-27
UA122780C2 (uk) 2021-01-06
IL280052B2 (en) 2023-09-01
CL2017001376A1 (es) 2018-02-16
CN111110677A (zh) 2020-05-08

Similar Documents

Publication Publication Date Title
BR112017011555A2 (pt) Composições que compreendem 2-((1-(2(4- fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona para o tratamento de esquizofrenia
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
IL257390B (en) Salts of 1-((4-methoxymethyl)-4-(((s2,r1)-2-phenyl-cyclopropylamine)methyl)piperidine-1-yl)methyl)-cyclobutane-carboxylic acid as lsd1 inhibitors
MX2017005935A (es) Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos.
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
MA39829A (fr) Combinaison
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
BR112017000584A2 (pt) inibidores da aldosterona sintase
CY1121909T1 (el) Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου
AR107163A1 (es) Inhibidores de quinasa
CO2019013649A2 (es) Composiciones farmacéuticas sólidas orales de dabigatrán etexilato
IN2013CH06150A (pt)
PL407399A1 (pl) 1,1-ditlenek 2-[2-(4-fenylopiperazyn-1-ylo)-2-oksoetylo]-3-(4-fluorobenzoilo)-4-hydroksy-2H-1,2-benzotiazyny o aktywności przeciwzapalnej i przeciwbólowej oraz sposób jego wytwarzania
PL408052A1 (pl) Nowa pochodna kwasu 5-amino-3-metylo-4-izoksazolokarboksylowego, sposób jej wytwarzania i zastosowanie

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014589-5 PROTOCOLO 870230063635 EM 20/07/2023 14:33.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/11/2015, OBSERVADAS AS CONDICOES LEGAIS